SEARCH RESULTS FOR: "Tag: ACAD"
REFINE YOUR SEARCH:
RECENT
Last Week(1)
Last Month(1)
ARTICLES/BLOGS
2019(1)
2018(6)
2017(7)
2016(20)
2015(14)
CATEGORIES
Analyst Downgrades(2)
Analyst Update(6)
Analyst Upgrades(2)
Buzz Stocks(7)
By the Numbers(1)
Earnings Preview(1)
Expectational Analysis(2)
General(7)
Intraday Option Activity(7)
Market Recap(2)
Midday Market Check(7)
Opening View(3)
Quantitative Analysis(1)
Stock Market News(4)
Stocks On the Move(8)

9/9/2019 10:26 AM
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced positive late-stage data for its drug pimavanserin in patents suffering from dementia-related psychosis. The San Diego-based biopharmaceutical firm ...
9/21/2018 9:53 AM
Shares of San Diego-based drug concern ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) are continuing yesterday's surge, with a 6.7% advance to trade at $20.39 out of the gate. Just one day after the Food a...
8/9/2018 10:45 AM
Shares of drug name ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) touched a five-year low of $12.77 out of the gate, but have since turned higher, as traders shrug off an earnings miss. The firm reported...
8/6/2018 11:52 AM
The Dow Jones Industrial Average (DJI) has clawed its way out of the red at the session's midpoint, overcoming a 1.3% drop for Intel (INTC) after the chip stock was downgraded at Barclays. Trade ...
6/29/2018 9:57 AM
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock is up 11.5% to trade at $16.80, after the Food and Drug Administration (FDA) approved new capsule dosing formulation and tablet strength for Nuplazid,...

Welcome to Schaeffer's Investment Research! We are a privately held provider of stock and options trading recommendations, options education, and market commentary, headquartered in Cincinnati, Ohio. Founded in 1981 by industry pioneer Bernie Schaeffer, we've since become a trusted source of research and analysis for individual investors and major financial media outlets alike.







Partner Center